

CONTRACT DRUG PRODUCT R&D | COMPLEX INJECTABLE FORMULATIONS

DDE Labs Fall 2019 Newsletter

PARTNERSHIP NEWS

Breakthrough Formulation Developed in Collaboration with DDE Labs

VERU-100 is a novel, proprietary peptide formulation that has been fast-tracked by the FDA for clinical development



Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company announced that it has a reached an agreement with FDA on an expedited regulatory pathway and clinical development strategy. Veru-100, developed at DDE Labs, has proven

multiple beneficial clinical attributes for addressing the androgen deprivation therapy market for advanced prostate cancer.

"I am particularly pleased that VERU-100 was internally developed by the Company in collaboration with DDE Labs and not acquired from a third party," said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru.

Chris Rhodes, Chief Executive Officer of DDE Labs commented, "Veru has been a great collaborator and we look forward to this exciting new therapy becoming available to patients."

More

PARTNERSHIP NEWS

CEO Chris Rhodes wins Biocom's DeviceFest Hot Seat Competition

Baywind Bioventures crowned "Hottest New Device Company in Southern California" for presenting JetCAP™ a revolutionary oral capsule device developed in collaboration with DDE Labs

Congratulations goes out to Chris who won Biocom's DeviceFest Hot Seat Competition on August 28, 2019.

The Hot Seat event hosted by Biocom has audience members listen to promising new technologies and then vote on the winner. Baywind Bioventures, an incubator for technology platforms developed at DDE Labs, presented its patented JetCAP™ technology.



JetCAP™ beat out other Hot Seat finalists Chris Memmott of Applied Infusion Technology and Ty Takayanagi, of Triple W.

Baywind Bioventures received a check for \$5,000 and will get a feature article in an upcoming issue of *Biocom Lifelines Magazine*.

<u>More</u>

PUBLICATIONS

Chris Rhodes Pens Chapter for Parenteral Medications, Fourth Edition



Our CEO has been very busy this summer, even taking time to write the chapter on Formulation of Depot Delivery Systems for the newest edition of *Parenteral Medications*.

Chris co-wrote the chapter with Nikita Malavia covering the history of depot delivery systems. It also explains suspension and biodegradable polymeric systems, implantable devices, and the future direction of depot delivery systems.

The new edition is available at book retailers now.

<u>More</u>

PEOPLE

DDE Summer Internship Program Comes to a Close

Fostering the next generation of Biotech professionals has always been important to DDE since day one. This summer saw our largest class of interns yet.

As they head back to college this fall, we wanted to give a big thank you for all their hard work. Thanks to Evan Clark and Ethan Eisele for their great work supporting the lab; Lauren Quan and Jason Martel for assisting the marketing department; and Ryan Lamkin and Dylan Sreshta for keeping everything running smoothly on the operations



If you know someone who might be a good fit as a laboratory, marketing, or operations intern, encourage them to submit a resume to info@ddelabs.com. We are currently looking for fall/winter interns.

Visit Our Website

Schedule A Meeting

Find DDE Labs At:



AAPS PharmSci 360

Mon, Nov 4, 2019 – Wed, Nov 6, 2019 Henry B. Gonzalez Convention Center, San Antonio, TX

Visit Us At Booth #651!

More